Result of AGM and Update

Proteome Sciences plc                             

                    (the "Proteome Sciences" or "Company")                     

                            AGM Results and Update                             

Cobham, England, 28 July 2008 - Proteome Sciences plc is pleased to announce
that at the Company's Annual General Meeting ("AGM") held earlier today
resolutions 1 to 7 were duly passed but resolution 8 was not carried following
a poll.

At today's AGM Dr Ian Pike, Chief Business Officer, provided a presentation on
the Commercial Value and Importance of Biomarkers. This presentation will
shortly be made available on the Company's website (www.proteomics.com).
Furthermore, the Company's Chairman, Steve Harris, made the following comments:

"It may be helpful for our shareholders to have a better understanding of the
Company's view of the potential market size and importance of our TMT® isobaric
tandem mass tag technology.

In 2006 estimates for isobaric tandem mass tags indicated that the overall
market size over the TMT® patent life was likely to be from $0.6bn to $1.4bn,
and the rapid 18% annual growth rates evidenced at that time in proteomics and
mass spectrometry services subsequently appear to have increased. In the second
half of 2007, Proteome Sciences presented the development of TMT Reference
Materialsâ„¢ and TMTcalibratorâ„¢, high value, high volume bespoke labelling
applications that address and open up substantial new markets and
opportunities.

In April 2008 Proteome Sciences announced the license agreement for TMT®
catalogue products with Thermo Fisher Scientific Inc., the global leader
serving science. Under the license arrangements with Thermo Fisher, Proteome
Sciences retained the use of TMT® for custom labelling services and its own
research. TMT Reference Materialsâ„¢ and TMTcalibratorâ„¢ are predicted to add
considerable additional revenue as the pharmaceutical industry and its
regulators require increasing access to technologies that improve the quality
and throughput of biomarker discovery validation and assay development. This
wider use profile increases the potential market size and value of TMT®. In
addition, custom applications in their own right through the ProteoSHOP®
services division is an untapped market and could match the estimates for TMT®
catalogue sales, and with greater returns.

As previously stated, the TMT® license agreement was an outstanding deal for
our company that should transform our prospects and provide strong cash flow
from signature fees, contract manufacturing payments and royalties on sales
with additional sales milestones. These should become increasingly visible as
we move into 2009. The development of fast, effective and cost efficient TMT®
workflows for the discovery, validation and development of assays for
biomarkers has been completed at a time when the pharmaceutical industry is
increasingly requiring access to biomarkers throughout the drug development
process to improve the output of their R&D programs. We are most encouraged by
the emerging profile and importance of biomarkers and the development of our
ProteoSHOP® services division.

With substantial progress made in the last 12 months we strongly believe that
we are exceptionally placed to capitalise on the growing significance of
biomarkers which should provide rapid revenue growth across all aspects of our
business."

Contact Proteome Sciences plc at www.proteomics.com

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director

Dr. Ian Pike, Chief Business Officer

Tel: [phone]

COAST Communications

Matt Baldwin

Tel: [phone]

IKON Associates

Adrian Shaw

Tel: [phone]

Landsbanki Securities (UK) Limited

Shaun Dobson / Claes Spång

Tel: [phone]

About Proteome Sciences:

Proteome Sciences plc (LSE : PRM) is a global leader in applied proteomics,
using high sensitivity proprietary techniques to detect and characterise
differentially expressed proteins in diseases for diagnostic, prognostic and
therapeutic applications.

ProteoSHOP® provides integrated proteomic services for biomarker discovery,
validation and measurement in clinical trials and in vitro diagnostics. Key
features include the proprietary isobaric tandem mass tag technology TMT® for
accurate and reliable biomarker quantification and the ability to rapidly
develop highly reproducible quantitative biomarker assays.

The main focus of its research addresses neurological, oncology and
cardiovascular conditions and has discovered blood biomarkers in stroke, brain
damage, solid organ transplant rejection and Alzheimer's disease. Proteome
Sciences is based in Cobham, UK with facilities in London and Frankfurt.